Authors: Hudis, C Fornier, M Riccio, L Lebwohl, D Crown, J Gilewski, T Surbone, A Currie, V Seidman, A Reichman, B Moynahan, M Raptis, G Sklarin, N Theodoulou, M Weiselberg, L Salvaggio, R Panageas, KS Yao, TJ Norton, L

Citation: C. Hudis et al., 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study, J CL ONCOL, 17(4), 1999, pp. 1118-1126

Authors: Khoo, K Brandes, L Reyno, L Arnold, A Dent, S Vandenberg, T Lebwohl, D Fisher, B Eisenhauer, E

Citation: K. Khoo et al., Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine. HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study, J CL ONCOL, 17(11), 1999, pp. 3431-3437

Authors: Hudis, C Seidman, A Baselga, J Raptis, G Lebwohl, D Gilewski, T Moynahan, M Sklarin, N Fennelly, D Crown, JPA Surbone, A Uhlenhopp, M Riedel, E Yao, TJ Norton, L

Citation: C. Hudis et al., Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy, J CL ONCOL, 17(1), 1999, pp. 93-100

Authors: DeMario, MD Ratain, MJ Vogelzang, NJ Mani, S Vokes, EE Fleming, GF Melton, K Johnson, S Benner, S Lebwohl, D

Citation: Md. Demario et al., A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14days every 28 days, CANC CHEMOT, 43(5), 1999, pp. 385-388